CBD Information

Home  Ι  News and Updates  Ι  Statutes and Rules  Ι  Contact Us

The increasing number of cannabis-derived products (including those products derived from hemp), especially cannabidiol (better known as “CBD”), that are being distributed and sold, are generating concerns with the public health community about product safety and drug interactions, truth-in-labeling, false health claims, and quality control.  Hawaii law prohibits adding any cannabis-derived substances to food, beverages or cosmetics for manufacture, distribution or sale.  The U.S. Food and Drug Administration (FDA) has not approved the use of CBD in over-the-counter products and does not consider these products safe.

Hawaii statutes are aligned with the FDA’s standards to protect the health of Hawaii residents, and support Hawaii Department of Health (DOH) policies that restrict the distribution of products not approved by the FDA.

Key Messages:

  • Products containing CBD are not generally considered safe and there may be potential health risks associated with them.
  • It is illegal to add CBD to food, beverages and cosmetics that are manufactured, distributed and sold in Hawaii.
  • CBD may not be sold as a “dietary supplement.”
  • CBD may not be marketed by asserting health claims because that would constitute prohibited misbranding or false advertising.
  • CBD is the active ingredient in an FDA-approved prescription drug. Therefore, it cannot be put into food, beverages and cosmetics, sold as a drug without a prescription, or marketed as a “dietary supplement.”

Questions and Answers about Cannabis-Derived Products, Including CBD

Sources:

Food and Drug Administration statement, “Statement from FDA Commissioner Scott Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds,” December 20, 2018:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628988.htm

Food and Drug Administration statement, “Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products,” April 2, 2019: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635048.htm

Hawaii Revised Statutes, Chapter 328:
https://www.capitol.hawaii.gov/hrscurrent/Vol06_Ch0321-0344/HRS0328/HRS_0328-.htm

Hawaii Administrative Rules, Chapter 11-50: https://health.hawaii.gov/san/files/2017/09/HAR-11-50-amended-9.1.2017.pdf

MedlinePlus: https://medlineplus.gov/druginfo/natural/1439.html

Centers for Disease Control and Prevention – Synthetic Cannabinoids: An Overview for Healthcare Providers: https://www.cdc.gov/nceh/hsb/chemicals/sc/healthcare.html#one

Centers for Disease Control and Prevention: Horth RZ, Crouch B, Horowitz BZ, et al. Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018. MMWR Morb Mortal Wkly Rep 2018;67:587–588. DOI: http://dx.doi.org/10.15585/mmwr.mm6720a5

Additional Resources:

FAQs from FDA: https://www.fda.gov/newsevents/publichealthfocus/ucm421168.htm

FDA Highlights on Epidiolex: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf

Journal of Clinical Pharmacology: White, C. (2019). A Review of Human Studies Assessing Cannabidiols (CBD) Therapeutic Actions and Potential. The Journal of Clinical Pharmacology. doi:10.1002/jcph.1387: https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1387